Lv4
634 积分 2025-06-26 加入
Feasibility of One-Day PET/CT Scanning Protocol with 68Ga-DOTA-FAPI-04 and 18F-FDG for the Detection of Ovarian Cancer Recurrence and Metastasis
6天前
已完结
Clinical Cytokine Assays Early in the Course of Cytokine Release Syndrome (CRS) after CAR-T Therapy Show Difference Among Patients with Severe CRS Versus Immune Effector Cell-Associated Hemophagocytic Syndrome (IEC-HS)
2个月前
已完结
How I treat HLH-like toxicities after immune effector cell therapy
2个月前
已关闭
Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial
3个月前
已完结
Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial
3个月前
已完结
Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial
3个月前
已完结
Engineering challenges and translational opportunities in emerging gene delivery platforms
4个月前
已完结
Tumor-intrinsic regulators of the immune-cold microenvironment of prostate cancer
5个月前
已完结
Prostate cancer
5个月前
已完结
mRNA lipid nanoparticle formulation, characterization and evaluation
5个月前
已完结
皖公网安备34019202002308
